Terumo Corporation Unsponsored ADR logo

Terumo Corporation Unsponsored ADR (TRUMY)

Market Open
16 Oct, 03:08 PM
OTC PINK OTC PINK
$
14. 71
+0.21
+1.4128%
$
21.52B Market Cap
39.65 P/E Ratio
52% Div Yield
2,913 Volume
0 Eps
$ 14.51
Previous Close
Add Transaction
Day Range
14.7 14.79
Year Range
12.08 17.81
Want to track TRUMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Recent Price Trend in Terumo (TRUMY) is Your Friend, Here's Why

Recent Price Trend in Terumo (TRUMY) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks | 1 year ago
Terumo (TRUMY) Is a Great Choice for 'Trend' Investors, Here's Why

Terumo (TRUMY) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks | 2 years ago
Here's Why Momentum in Terumo (TRUMY) Should Keep going

Here's Why Momentum in Terumo (TRUMY) Should Keep going

Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 2 years ago
Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice

Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 2 years ago
What Makes Terumo (TRUMY) a New Buy Stock

What Makes Terumo (TRUMY) a New Buy Stock

Terumo (TRUMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 2 years ago
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Zacks | 2 years ago
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.

Zacks | 2 years ago
Terumo Corporation (TRUMY) Q4 2024 Earnings Call Transcript

Terumo Corporation (TRUMY) Q4 2024 Earnings Call Transcript

Terumo Corporation (OTCPK:TRUMY) Q4 2024 Results Conference Call May 14, 2024 4:30 AM ET Company Participants Jin Hagimoto - CFO Hikaru Samejima - President, CEO & Director Jin Hagimoto I'm Hagimoto, Terumo's CFO. I would like to present an overview of the year-end financial results for the fiscal year ending March 31, 2024.

Seekingalpha | 2 years ago